Related Experiment Video
Updated: Jul 10, 2026
10:42
Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid
Published on: April 11, 2019
PACAP and its receptor VPAC1 regulate megakaryocyte maturation: therapeutic implications
Kathleen Freson1, Karen Peeters, Rita De Vos
1Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium. kathleen.freson@med.kuleuven.be
Blood
|November 15, 2007
Summary
VPAC1 signaling normally limits megakaryocyte production. Inhibiting this pathway, using specific antibodies, stimulates megakaryocyte differentiation and boosts platelet counts, aiding recovery in thrombocytopenia.
Area of Science:
- Hematology
- Molecular Biology
- Cell Signaling
Background:
- Megakaryocytes and platelets express the VPAC1 receptor, activated by pituitary adenylyl cyclase-activating peptide (PACAP) and vasoactive intestinal peptide (VIP).
- VPAC1 signaling's role in megakaryopoiesis, the process of megakaryocyte development, was previously unclear.
Purpose of the Study:
- To investigate the regulatory role of VPAC1 signaling in megakaryopoiesis.
- To explore the therapeutic potential of inhibiting VPAC1 signaling for thrombocytopenia.
Main Methods:
- Studied patients with trisomy 18p and PACAP overexpression, alongside transgenic mice overexpressing PACAP.
- Utilized in vitro differentiation of hematopoietic stem cells (CD34+ cells).
- Administered neutralizing monoclonal antibodies against PACAP (PP1A4) and VPAC1 (23A11) in vitro and in vivo.
Main Results:
- PACAP overexpression in patients and mice led to reduced mature megakaryocytes and mild thrombocytopenia.
- Inhibition of VPAC1 signaling via antibodies (PP1A4, 23A11) stimulated megakaryopoiesis and increased platelet counts.
- Antibodies enhanced platelet recovery in models of myelosuppressive therapy and GATA1-deficient congenital thrombocytopenia.
Conclusions:
- VPAC1 signaling acts as a brake on normal megakaryopoiesis.
- Inhibiting VPAC1 signaling promotes megakaryocyte differentiation and platelet production.
- Targeting VPAC1 offers a potential therapeutic strategy for enhancing platelet recovery in various thrombocytopenic conditions.
Related Concept Videos
01:01Regulation of Hematopoietic Stem Cells
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
01:15Receptor Downregulation in MVBs
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
01:15Differentiation of Common Myeloid Progenitor Cells
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
01:19Multipotency of Hematopoietic Stem Cells
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...